1-methyl-1,2,3,4-tetrahydro-2-quinazolinone | 19270-60-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1-methyl-1,2,3,4-tetrahydro-2-quinazolinone
• 英文别名: 1-methyl-3,4-dihydroquinazoline-2(1H)-one；1-Methyl-3,4-dihydro-1H-chinazolinon-(2)；3,4-Dihydro-1-methyl-2(1H)-quinazolinone；1-methyl-3,4-dihydro-1H-quinazolin-2-one；1-methyl-3,4-dihydroquinazolin-2-one
• CAS: 19270-60-1
• 化学式: C₉H₁₀N₂O
• 分子量: 162.191
• InChiKey: MVCFDHLQJVJMDE-UHFFFAOYSA-N

物化性质

• 熔点：
  183-184 °C
• 沸点：
  372.6±35.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-methyl-1,2,3,4-tetrahydro-2-quinazolinone 、 3-[4-(2-chloroethyl)-1-piperazinyl]-1,2-benzisoxazole 在 氢氧化钾 、 四丁基溴化铵 作用下， 以 甲苯 为溶剂， 反应 5.0h， 以59%的产率得到
  参考文献：
  名称：

  New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives with atypical antipsychotic binding profile

  摘要：

  New 3-benzisothiazolyl and 3-benzisoxazolylpiperazine derivatives were synthesised and their 5-HT1A, 5-HT2A and D-2 receptor binding affinities evaluated. The compounds displayed high affinity for the 5-HT2A receptor combined with moderate to low 5-HT1A and D-2 affinities. Two of them, 18 and 25, have been selected for further pharmacological studies to be evaluated as potential atypical antipsychotics. (C) 2002 Editions scientifiques et medicales Elsevier SAS. All rights reserved.

  DOI：

  10.1016/s0223-5234(02)01391-0
• 作为产物：
  描述：

  2-(aminomethyl)-N-methylaniline 在 palladium on activated charcoal 氢气 、 三乙胺 作用下， 以 吡啶 、 N,N-二甲基甲酰胺 为溶剂， 反应 21.5h， 生成 1-methyl-1,2,3,4-tetrahydro-2-quinazolinone
  参考文献：
  名称：

  Study of biscarbamates derived from 2-aminobenzylamines as models for alcohol prodrugs

  摘要：

  Unsubstituted N-arylcarbamate of title compound does not cyclize to the corresponding cyclic urea: with ROH liberation, under mild conditions (40 degrees C). Substitution of the benzylic position by two methyl groups promotes slow cyclisation while N-methylation of the N-aryl carbamate has a more important effect. Relative cyclisation rates are in agreement with barrier heights obtained from ab initio calculations. The calculations also suggest that the highest cyclisation rate of the latter is a consequence of the steric hindrance caused by the N-methyl substituent. (C) 1999 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4020(99)00139-8

文献信息

• 一种含氮氢类化合物的烷基化方法及其应用
  申请人：江南大学

  公开号：CN108503583B

  公开（公告）日：2020-10-09

  本发明公开了一种含氮氢类化合物的烷基化方法及其应用，属于有机化合物合成技术领域。本发明提供了一系列以N,N‑二甲基甲酰胺二烷基缩醛作为烷基源、在无金属参与条件下对含N‑H杂环化合物(II)进行氮烷基化反应的方法，得到氮原子上的氢原子被R1取代的产物。本发明方法反应高效、收率高、反应后处理简单，操作简便；反应条件温和，无金属参与；反应底物官能团容忍性高，底物范围广和容易制备；反应放大后反应效率仍然高，适合大规模工业化生产。
• Lanthanide-catalyzed cyclocarbonylation and cyclothiocarbonylation: a facile synthesis of benzannulated 1,3-diheteroatom five- and six-membered heterocycles
  作者：YuFeng Jing、RuiTing Liu、YangHui Lin、XiGeng Zhou

  DOI：10.1007/s11426-014-5149-0

  日期：2014.8

  La[N(SiMe3)2]3 proves to be an efficient catalyst system for the cyclocarbonylation of 1,2-disubstituted benzenes with isocyanates. In this approach, aryl/alkyl isocyanates react with o-phenylenediamine, o-aminophenol, o-aminothiophenol, catechols and anilines ortho-substituted by CH2NH2 and CONH2 to form, respectively, the corresponding benzimidazolones, benzoxazolones, benzothiazolones, benzodioxolones, 3,4-dihydroquinazolin-2(1H)-one, and quinazolinediones. These results represent the first example of lanthanide-catalyzed carbonylation. This methodology is also applicable for the preparation of various benzannulated 1,3-diheteroatom cyclic thioketones starting from aryl/alkyl isothiocyanates or CS2 in good to excellent yields. Based on the results of experiments performed using an o-aminobenzamido dianion lanthanide complex, a general mechanism, involving the tandem reaction of two lanthanide-ligand bonds with one heterocumulene molecule, is proposed as well.

  La[N(SiMe3)2]3 被证明是一种有效催化体系，用于异氰酸酯与1,2-二取代苯的环碳酰化反应。在此过程中，芳基/烷基异氰酸酯与邻苯二胺、邻氨基苯酚、邻氨基硫酚、邻苯二酚、以及邻位被CH2NH2和CONH2取代的苯胺反应，分别生成相应的苯并咪唑酮、苯并噁唑酮、苯并噻唑酮、苯并二氧六环酮、3,4-二氢喹唑啉-2(1H)-酮以及喹唑啉二酮。这些结果代表了镧系元素催化碳酰化反应的首例。这一方法还适用于以芳基/烷基异硫氰酸酯或CS2为原料，在良好至优异的产率下制备各种苯并稠合的1,3-二杂原子环硫酮。基于使用邻氨基苯甲酰胺双负离子镧系络合物进行的实验结果，提出了一个涉及镧系元素-配体键与单一杂累积分子连续反应的通用机制。
• N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
  申请人：Antel Jochen

  公开号：US20070149512A1

  公开（公告）日：2007-06-28

  The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.

  本发明涉及具有化学式I的新型N-磺胺基哌啶酰胺及其生理上可接受的酸盐，包括含有它们的药物组合物，其制备方法，以及用于治疗肥胖及其伴随和/或继发疾病以及相关或其他病症的用途。
• Benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds, cardiotonic
  申请人：Rorer Pharmaceutical Corporation

  公开号：US04868300A1

  公开（公告）日：1989-09-19

  Compounds of the formula ##STR1## wherein: z is O or I; X is ##STR2## a and b are 0, 1, or 2 and a+b=0, 1 or 2; R, R.sup.1, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each independently hydrogen, alkyl or aralkyl; R.sub.n is hydrogen, alkyl, aralkyl, acyl, carbalkoxy, carbamyl, carbalkoxyalkyl, hydroxyalkyl, alkoxyalkyl or amidino; R.sup.5 groups on vicinal carbon atoms may together form a carbon-carbon double bond when a or b=2; R groups on vicinal carbon atoms may together form a carbon-carbon double bond when R.sub.n is hydrogen and z=1; R.sup.4 and R.sup.5 geminal groups may together form a spiro substituent, --(CH.sub.2).sub.d --, where d is 2 to 5; R.sup.5 and R.sup.6 groups may together form a carbon-nitrogen double bond when R.sub.3 is hydrogen and a+b=1; R.sup.2 is hydrogen or --(CH.sub.2).sub.y --Y where y is 1-3; Y is hydrogen, --O--R.alpha., --S-R.alpha. or ##STR3## R.alpha. is hydrogen, alkyl, cycloalkyl or acyl; R.beta. is hydrogen or alkyl; and R.alpha. and R.beta. together may form a 3-7 membered ring which may also contain 0-2 additional hetero atoms selected from N, O and S; provided that when a+b=0 and z is 1, then at least one of R.sub.n, R, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is other than hydrogen; and pharmaceutically acceptable salts thereof, and methods for increasing cardiac contractility using said compounds.

  式为##STR1##的化合物，其中：z为O或I；X为##STR2##；a和b分别为0、1或2，且a+b=0、1或2；R、R.sup.1、R.sup.3、R.sup.4、R.sup.5和R.sup.6分别独立地为氢、烷基或芳基烷基；R.sub.n为氢、烷基、芳基烷基、酰基、羧烷氧基、氨基甲酰基、羧烷氧基烷基、羟基烷基、烷氧基烷基或酰胺基；当a或b=2时，邻位碳原子上的R.sup.5基团可一起形成碳-碳双键；当R.sub.n为氢且z=1时，邻位碳原子上的R基团可一起形成碳-碳双键；R.sup.4和R.sup.5的伪位基团可一起形成螺环取代基，--(CH.sub.2).sub.d--，其中d为2至5；当R.sub.3为氢且a+b=1时，R.sup.5和R.sup.6基团可一起形成碳-氮双键；R.sup.2为氢或--(CH.sub.2).sub.y--Y，其中y为1-3；Y为氢、--O--R.alpha.、--S-R.alpha.或##STR3##；R.alpha.为氢、烷基、环烷基或酰基；R.beta.为氢或烷基；且R.alpha.和R.beta.一起可形成一个含有3-7个成员的环，该环还可以包含0-2个来自N、O和S的额外杂原子；但是当a+b=0且z为1时，至少其中一个R.sub.n、R、R.sup.1、R.sup.2、R.sup.3、R.sup.4、R.sup.5和R.sup.6不是氢；以及其药用盐，以及使用所述化合物增加心脏收缩力的方法。
• [EN] BENZODIAZINONE-PYRIDAZINONE AND HYDROXY-PYRAZOLYL COMPOUNDS, CARDIOTONIC COMPOSITIONS INCLUDING THE SAME, AND THEIR USES
  申请人：RORER INTERNATIONAL (OVERSEAS) INC.

  公开号：WO1987003201A1

  公开（公告）日：1987-06-04

  (EN) A method for increasing cardiotonic contractility in humans or other animals using a class of benzodiazinone-pyridazinone and hydroxy-pyrazolyl compounds and pharmaceutical compositions including the same.(FR) Procédé pour augmenter la contractilité cardiotonique chez les humains ou d'autres animaux, mettant en o^euvre une classe de composés de benzodiazinone-pyridazinone et d'hydroxy-pyrazolyl, et compositions pharmaceutiques les contenant.

  一种使用苯二氮卓酮-吡啶二酮和羟基吡唑基化合物类增强人类或其他动物心脏肌力收缩的方法，以及包含这些化合物的药物组合物。